# Salubris Biotherapeutics

Salubris Biotherapeutics Unveils Promising Clinical Data for Novel ADC, Signaling China’s Global Precision Oncology Push

Salubris Biotherapeutics has reported positive Phase 1/2 clinical data for its 5T4-targeting ADC, JK06, at the AACR 2026 conference. The drug shows promising safety and efficacy in treating advanced lung and breast cancers, marking a key advancement in the company's international clinical pipeline.